Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the griffin and master studies Meeting Abstract
| Authors: | Callander, N.; Silbermann, R.; Kaufman, J. L.; Godby, K. N.; Laubach, J. P.; Schmidt, T. M.; Sborov, D. W.; Medvedova, E.; Reeves, B.; Dhakal, B.; Rodriguez, C.; Chhabra, S.; Chari, A.; Bal, S.; Anderson, L. D. Jr; Dholaria, B.; Nathwani, N.; Hari, P.; Shah, N.; Bumma, N.; Holstein, S. A.; Costello, C.; Jakubowiak, A.; Wildes, T. M.; Orlowski, R. Z.; Shain, K. H.; Cowan, A. J.; Pei, H.; Cortoos, A.; Patel, S.; Lin, T. S.; Giri, S.; Costa, L. J.; Richardson, P. G.; Usmani, S.; Voorhees, P. M. |
| Abstract Title: | Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the griffin and master studies |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 10144 |
| End Page: | 10147 |
| Language: | English |
| ACCESSION: | WOS:000893230303069 |
| DOI: | 10.1182/blood-2022-160451 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
